MSM Protein Technologies is an early drug development company focused on advancing its own first-in-class, fully human antibodies targeting several GPCRs.
MSM was founded in 2005 as an antibody drug discovery company focused on difficult membrane protein targets. Our proprietary fully-integrated technology platform allows for rapid and reliable generation of human therapeutic antibodies using phage display libraries. Recently, the platform was extended to mammalian cell display libraries and immunization approaches. We have successfully completed a dozen projects aimed at generating functional human antibodies to GPCRs, in collaborative projects and for our internal pipeline. The company is seeking partners for de novo discovery as well as to advance our proprietary antibodies for the treatment of oncologic, autoimmune, inflammatory and respiratory diseases into clinical development.
Meet Our Board of Directors:
Chairman of the Board and Co-Founder
Davis Farmer is the Chairman of the Board and co-founder of MSM. He brings 20 years of experience heading biotechnology companies to MSM and more than 30 years experience in company start-ups and deal formation. In addition to MSM, Mr. Farmer co-founded Cellular Technology Limited, the world's leader in T-cell research analytics and was the founding CEO of Pacific Edge Limited, now the largest human healthcare biotech company in New Zealand. He has also served on the boards of numerous companies including Biomedical Research Models, Virogen Limited (UK), Array Biosciences, ObeSys Ltd. (UK), the New Zealand Seed Fund and the Ulysses Group. Mr. Farmer holds a business degree from the University of Vermont.
Chief Operating Officer, President and Co-Founder
David Kreimer, Ph.D. is the President and Chief Operating Officer of MSM Protein Technologies. Dr. Kreimer has played a vital role in steering the company forward since its inception in 2005. With over 30 years of experience in the biological sciences, he brings both sophisticated academic expertise and masterful leadership to MSM. He was Vice President of Research at Tienta Sciences, Inc./InProteo Consortium. David Kreimer served as co-founder, President and Chief Executive Officer of Array BioScience Corporation. Dr. Kreimer consulted for several companies such as Clontech Laboratories, Inc. He performed research in advanced institutions including the Weizmann Institute of Science and University of California, Berkeley and earned his Ph.D. in Biophysics from the Institute of Biological Physics at the USSR Academy of Sciences.
Chief Scientific Officer and Co-Founder
Dr. Kim is the Chief Scientific Officer of MSM Protein Technologies. He has 25 years of experience in the biochemical and biomedical sciences, and an outstanding record of creative leadership, strategic planning, design and successful implementation of major company projects. Prior to joining MSM, he served as a Senior Scientist at Burnham Medical Research Institute and Senior Scientist at Structural Bioinformatics Inc. Dr. Kim has performed research at the Department of Molecular Biology, at Harvard Medical School and the Department of Chemistry and Biochemistry at UCLA. He obtained his Ph.D. in Biochemistry at the A.N. Bach Institute of Biochemistry of the Russian Academy of Sciences in Moscow, Russia.
Partner at BioCity Development
Dr. Hentschel has worked in the pharmaceutical industry for over 30 years, leading a variety of private and public institutions. He worked as founding CEO of the Switzerland-based Medicines for Malaria Ventures (MMV). Over his 10 years in that role, he grew the nonprofit from a small start-up to an institution managing one of the largest anti-malarial project portfolios in the world. Prior to that, he was Senior Vice President and Chief Scientific Officer at Centocor and was instrumental to its merger with Johnson & Johnson in 1999. Between 1978 and 1997, Chris Hentschel was the Chief Executive Officer and Scientific Director of the UK Medical Research Council's Collaborative Centre. There, he managed over 40 drug discovery and development collaborations. From 1983 to 1987 he was head of the department of Molecular Genetics at Celltech Ltd. He earned his PhD in biochemistry from King’s College, University of London. He is currently a partner with Bio City Development Co supporting the establishment of a world-class research base at Bio Istanbul. Dr. Hentschel also serves on the boards of institutions such as the Global Medical Forum Foundation and the Infectious Disease Research Institute.